AstraZeneca stock stays in focus as Q3 growth backs 2026 outlook
Published on 11/04/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and pipeline support outlook
- AstraZeneca reported 7% constant-currency revenue growth in the first nine months of 2026.
- Core EPS rose 14%, while Oncology revenue increased 16% to 21.9 billion dollars.
- Management reaffirmed its full-year 2026 revenue and Core EPS guidance.
AstraZeneca reported strong commercial momentum for the first nine months of 2026 and kept its full-year outlook unchanged. The company published the results on Friday, October 30, with total revenue up 7% at constant exchange rates and Core EPS up 14%.
The AstraZeneca results release said growth in Oncology, Respiratory and Immunology, and Rare Disease offset pressure from loss of exclusivity for Farxiga and Brilinta as well as volume-based procurement in China. The company also reported 47 approvals in major regions since its fourth-quarter 2025 results, including first approvals for four new medicines.
Pipeline adds longer-term focus
Oncology generated 21.9 billion dollars in nine-month revenue, up 16% at constant exchange rates and representing the largest therapy area. Rare Disease revenue rose 11%, while BioPharmaceuticals revenue declined 5% as cardiovascular, renal and metabolism products faced exclusivity pressure.
AstraZeneca said it had recorded 12 positive Phase III programme readouts year to date and that upcoming 2027 readouts have potential peak-year revenue of more than 20 billion dollars. For 2026, the company expects total revenue to rise by a mid-to-high single-digit percentage and Core EPS by a low double-digit percentage at constant exchange rates.
The real-time quote of AstraZeneca stock was 168.73 euros on Lang & Schwarz at 18:15 CET on Wednesday, November 4, 2026. That is 2.30% above the 164.93 euros cited in the November 3 report. The since-report comparison is a separate reference from the regular Xetra daily benchmark.
AstraZeneca PLC
- ISIN: GB0009895292
- Quote: 168.73 euros on Lang & Schwarz, November 4, 2026, 18:15 CET
- Since November 3 report: 2.30% higher than 164.93 euros
- Nine-month 2026 revenue: 46.881 billion dollars, up 7% at constant exchange rates
- Nine-month 2026 Core EPS: 8.00 dollars, up 14% at constant exchange rates
The FTSE 100 is the relevant UK market backdrop for AstraZeneca investors.
More news and analyses on AstraZeneca stock remain focused on pipeline execution, commercial growth and delivery of the 2026 outlook.
